Last reviewed · How we verify
Spironolactone 50 mg
At a glance
| Generic name | Spironolactone 50 mg |
|---|---|
| Sponsor | Wake Forest University Health Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Spironolactone for Pulmonary Arterial Hypertension (PHASE2)
- HEART: Pilot Randomized Controlled Trial (PHASE1, PHASE2)
- Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure. (NA)
- Spironolactone and XPB-1 Integrity in the TFIIH Complex (NA)
- Pulmonary Artery Denervation for Heart Failure With Preserved Left Ventricular Ejection Fraction (NA)
- Hypoglycemia and Autonomic Nervous System Function-B (PHASE4)
- Polypill Strategy for Heart Failure With Reduced Ejection Fraction (PHASE2)
- Radiofrequency Ablation for Polymorphic Ventricular Tachycardia With Heart Failure (RFCA for PMVT-HF) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Spironolactone 50 mg CI brief — competitive landscape report
- Spironolactone 50 mg updates RSS · CI watch RSS
- Wake Forest University Health Sciences portfolio CI